Syracuse

[18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal

Archive ouverte

Masse, Mathilde | Chardin, David | Tricarico, Pierre | Ferrari, Victoria | Martin, Nicolas | Otto, Josiane | Darcourt, Jacques | Comte, Victor | Humbert, Olivier

Edité par CCSD ; Springer Verlag (Germany) [1976-....] -

International audience. Abstract Aim To determine the long-term prognosis of immune-related response profiles (pseudoprogression and dissociated response), not covered by conventional PERCIST criteria, in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs). Methods 109 patients were prospectively included and underwent [ 18 F]FDG-PET/CT at baseline, after 7 weeks (PET interim 1), and 3 months (PET interim 2) of treatment. On PET interim 1, tumor response was assessed using standard PERCIST criteria. In the event of PERCIST progression at this time-point, the study design provided for continued immunotherapy for 6 more weeks. Additional response patterns were then considered on PET interim 2: pseudo-progression (PsPD, subsequent metabolic response); dissociated response (DR, coexistence of responding and non-responding lesions), and confirmed progressive metabolic disease (cPMD, subsequent homogeneous progression of lesions). Patients were followed up for at least 12 months. Results Median follow-up was 21 months. At PET interim 1, PERCIST progression was observed in 60% (66/109) of patients and ICPI was continued in 59/66. At the subsequent PET interim 2, 14% of patients showed PsPD, 11% DR, 35% cPMD, and 28% had a sustained metabolic response. Median overall survival (OS) and progression-free-survival (PFS) did not differ between PsPD and DR (27 vs 29 months, p = 1.0; 17 vs 12 months, p = 0.2, respectively). The OS and PFS of PsPD/DR patients were significantly better than those with cPMD (29 vs 9 months, p < 0.02; 16 vs 2 months, p < 0.001), but worse than those with sustained metabolic response (p < 0.001). This 3-group prognostic stratification enabled better identification of true progressors, outperforming the prognostic value of standard PERCIST criteria (p = 0.03). Conclusion [ 18 F]FDG-PET/CT enables early assessment of response to immunotherapy. The new wsPERCIST (“wait and see”) PET criteria proposed, comprising immune-related atypical response patterns, can refine conventional prognostic stratification based on PERCIST criteria. Trial registration HDH F20230309081206. Registered 20 April 2023. Retrospectively registered.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion